Chris Ryan

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

The FDA approved Guardant360 CDx as a companion diagnostic for vepdegestrant in ER-positive advanced or metastatic breast cancer with ESR1 mutations.

Orca-Q Receives FDA RMAT Designation for High-Risk Hematologic Malignancies.

The FDA approved vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least 1 line of endocrine therapy.

The FDA ODAC voted against the clinical benefit of switching to camizestrant after the emergence of an ESR1 mutation in HR-positive breast cancer.

The April 30, 2026, FDA ODAC meeting will focus on data from SERENA-6 for camizestrant in hormone receptor–positive, ESR1-mutated advanced breast cancer.

The April 30, 2026, FDA ODAC meeting will focus on data from CAPItello-281 for capivasertib plus abiraterone in PTEN-deficient mHSPC.

Elranatamab improved PFS vs SOC combination therapy in relapsed/refractory multiple myeloma, meeting the primary end point of the MagnetisMM-5 trial.

A data monitoring committee recommended halting the phase 3 FLASH2 trial investigating HyBryte in CTCL due to futility.

Data from a real-world analysis demonstrated the efficacy and safety of CAR T-cell therapy in primary mediastinal B-cell lymphoma.

The FDA has extended the target action date to review a BLA seeking the approval of subcutaneous isatuximab for multiple myeloma.

China’s NMPA approved belantamab mafodotin plus Vd for the treatment of relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Bortezomib maintenance was associated with lower rates of moderate-to-severe cGVHD in newly diagnosed multiple myeloma after allo-HSCT.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Sharon Castellino, MD, MSc, discusses the significance of the FDA approval of nivolumab plus AVD for stage III/IV classical Hodgkin lymphoma.

Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs.

Aaron Gerds, MD, details the rationale behind investigating agents targeting CALR mutations and other novel therapies in myeloproliferative neoplasms.

The allogeneic CAR T-cell therapy cema-cel improved MRD negativity rates vs observation as first-line consolidation in LBCL.

Pirtobrutinib plus venetoclax and rituximab improved PFS in relapsed/refractory CLL/SLL, meeting the primary end point of BRUIN CLL-322.

Ibrutinib given prior to apheresis was associated with improved outcomes with tisagenlecleucel vs postapheresis administration in relapsed/refractory LBCL.

Zevor-cel produced durable responses in patients with relapsed/refractory multiple myeloma following at least 3 prior lines of therapy.

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

Jan Philipp Bewersdorf, MD, FACP, detailed findings from a meta-analysis and considerations for the use of luspatercept for anemia in lower-risk MDS.

GATA2 variants retain enhancer activity, alter differentiation, and may link inflammation to hematologic malignancy risk.

Use of ruxolitinib before, during, and after allogeneic stem cell transplant was associated with low rates of GVHD in myelofibrosis.

The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.

In a post hoc indirect comparison, data showed zanubrutinib was linked to improved PFS vs acalabrutinib/venetoclax in patients with treatment-naive CLL.

C. Ola Landgren, MD, PhD, discusses the development of the AI risk-stratification model CORAL and its potential role in individualizing myeloma care.

The EMA’s CHMP has recommended the approval of subcutaneous isatuximab via on-body injector for the treatment of multiple myeloma.

Subcutaneous daratumumab was approved in Europe for patient or caregiver administration in multiple myeloma.